IsoRay signs US deal with BrachySciences
This article was originally published in Clinica
IsoRay has signed up BrachySciences, an Oxford, Connecticut-based subsidiary of medtech firm Biocompatibles, as the US distributor of its Proxcelan Cesium-131 brachytherapy seeds. The two firms have signed an exclusive deal, which IsoRay (Richland, Washington) believes will increase its presence in the US prostate cancer therapy market. BrachySciences will also distribute the product in Puerto Rico. Financial terms of the deal were not disclosed. According to IsoRay, studies have demonstrated that Cesium-131 is able to deliver the required dose to prostate cancer patients, whilst potentially reducing unnecessary dose to critical structures such as the urethra and rectum.
You may also be interested in...
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals